Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ischemia
Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
July 5th, 2007
Nuvelo, Inc. (NASDAQ:NUVO) announced the publication of the Phase 2 proof-of-concept data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 clinical trial (N=3D255) in the June 26th issue of the Journal of American College of Cardiology (JACC), demonstrating that higher-dose (greater than or equal to 7.5 mcg/kg) recombinant nematode anticoagulant protein c2 (rNAPc2) reduced the incidence and duration of ischemia as measured by 7-day continuous electrocardiogram (ECG) by more than 50% and did not statistically significantly increase bleeding in patients being treated with standard antithrombotics and an early invasive approach for non-ST-elevation acute coronary...
Source: Blood Weekly (2007-07-05)
|
|
|
